You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adrenergic Alpha-1 Receptor Antagonists

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Hanzhou, Zhejiang, China
    the Second Affiliated Hospital of Zhejiang Univercity School of
Apr 23, 2023

Primary Aldosteronism Trial in Montréal (Renin measurements)

Not yet recruiting
  • Primary Aldosteronism
  • Renin measurements
  • Montréal, Quebec, Canada
    Hôpital du Sacré-Coeur de Montréal
Oct 30, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

IL-1ß and Its Receptor Antagonists in Treatment of Severe

Withdrawn
  • Critical Illness
  • Sepsis, Severe
    • (no location specified)
    Jun 13, 2022

    Outcome Trial (Alpha-Agonist, a-adrenergic receptor agonist)

    Not yet recruiting
    • Outcome
    • (no location specified)
    Nov 28, 2023

    Outcome Trial (Alpha-Agonist, a-adrenergic receptor agonist)

    Not yet recruiting
    • Outcome
    • (no location specified)
    Nov 28, 2023

    Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

    Not yet recruiting
    • Adverse Effect
    • (no location specified)
    Nov 28, 2023

    Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

    Not yet recruiting
    • Adverse Effect
    • (no location specified)
    Nov 28, 2023

    Cardiomyopathy, Dilated, Heart Failure, Autoantibodies Trial in Belgrade, Belgrad (BC 007)

    Active, not recruiting
    • Cardiomyopathy, Dilated
    • +2 more
    • BC 007
    • Belgrade, Serbia
    • +2 more
    Jul 19, 2022

    Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

    Not yet recruiting
    • Hematologic Malignancy
    • +21 more
    • (no location specified)
    Feb 9, 2023

    Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease Trial in Los Angeles (Terazosin

    Recruiting
    • Symptomatic Parkinson Disease
    • +2 more
    • Terazosin therapy
    • Los Angeles, California
      Cedars Sinai Medical Center
    Aug 23, 2022

    Type 2 Diabetes, Obesity Trial in Sherbrooke (drug, other, diagnostic test, procedure)

    Recruiting
    • Type 2 Diabetes
    • Obesity
    • Formoterol Fumarate 12 micrograms Inhalation Powder
    • +8 more
    • Sherbrooke, Quebec, Canada
      Centre de recherche du CHUS
    Sep 22, 2022

    Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV Trial in Iowa City, Rochester, Madison ([212Pb]VMT01)

    Not yet recruiting
    • Melanoma (Skin)
    • +5 more
    • Iowa City, Iowa
    • +2 more
    Dec 8, 2022

    Exercise, Histamine Trial in Ghent (Placebo: Placebo + exercise training., H1 blockade: H1 receptor antagonist + exercise

    Active, not recruiting
    • Exercise
    • Histamine
    • Placebo: Placebo + exercise training.
    • +2 more
    • Ghent, Oost-Vlaanderen, Belgium
      Department of movement and sports sciences, Ghent University, Be
    Nov 8, 2022

    Fanconi Anemia, Severe Aplastic Anemia, MDS Trial in Minneapolis (Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY)

    Recruiting
    • Fanconi Anemia
    • +2 more
    • Total Body Irradiation (TBI) (Plan 1)
    • +8 more
    • Minneapolis, Minnesota
      Masonic Cancer Center at University of Minnesota
    Nov 2, 2022

    Opioid Use Disorder, Opioid Withdrawal Trial (BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo)

    Not yet recruiting
    • Opioid Use Disorder
    • Opioid Withdrawal
    • BXCL501 (180 micrograms)
    • +3 more
    • (no location specified)
    Jan 24, 2023

    Healthy Volunteers Trial in New York (Clonidine Pill)

    Withdrawn
    • Healthy Volunteers
    • Clonidine Pill
    • New York, New York
      Weill Cornell Medicine
    Jul 14, 2021

    Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 Trial in United States (drug, other,

    Active, not recruiting
    • Bilateral Breast Carcinoma
    • +11 more
    • Scottsdale, Arizona
    • +11 more
    Jan 12, 2023

    B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

    Recruiting
    • B-Cell Lymphoma
    • +4 more
    • 19(T2)28z1xx TRAC T cell
    • New York, New York
      Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    Feb 24, 2023

    Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer Trial in United States (STRO-002, Bevacizumab)

    Recruiting
    • Ovarian Cancer
    • +4 more
    • Tampa, Florida
    • +5 more
    Aug 1, 2022

    Delirium, Cognitive Decline, Frailty Trial in Bergen, Oslo, Trondheim (Dexmedetomidine, Clonidine, Natriumchlorid)

    Recruiting
    • Delirium
    • +2 more
    • Bergen, Norway
    • +3 more
    Apr 25, 2022

    A Pan-European Post-Authorisation Safety Study: Risk of

    Not yet recruiting
    • Pancreatic Cancer
    • Exenatide
    • Non-GLP-1 RA based glucose lowering drugs
    • (no location specified)
    Dec 21, 2022